• Je něco špatně v tomto záznamu ?

Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis

E. Dolezelova, E. Stein, G. Derosa, P. Maffioli, P. Nachtigal, A. Sahebkar,

. 2017 ; 83 (7) : 1380-1396. [pub] 20170310

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu srovnávací studie, časopisecké články, metaanalýza, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18025167
E-zdroje Online Plný text

NLK Free Medical Journals od 1974 do 2020
PubMed Central od 1974 do 2020
Europe PubMed Central od 1974 do Před 1 rokem
Wiley Free Content od 1997 do Před 1 rokem

AIMS: Statins are known to influence the status of adipokines, which play a key role in the pathophysiology of cardiometabolic diseases. As the effect of ezetimibe as an add-on to statin therapy on the impact of statins on plasma adipokines levels is currently unclear, the aim of the present study was to investigate this through a meta-analysis of controlled trials. METHODS: A systematic review was performed, followed by a bibliographic search in PubMed, Medline, SCOPUS, Web of Science and Google Scholar databases. Quantitative data synthesis was performed using a fixed- or random-effects model (based on the level of interstudy heterogeneity) and the generic inverse variance weighting method. Effect sizes were expressed as standardized mean difference (SMD) and 95% confidence interval (CI). RESULTS: Meta-analysis of 23 controlled trials did not suggest any significant effect of adding ezetimibe on top of statin therapy on plasma concentrations of adiponectin (SMD 0.34, 95% CI -0.28, 0.96; P = 0.288), leptin (SMD -0.75, 95% CI: -2.35, 0.85; P = 0.360), plasminogen activator inhibitor 1 (SMD -1.06, 95% CI: -2.81, 0.69; P = 0.236) and interleukin 6 (SMD 0.30, 95% CI: -0.08, 0.67; P = 0.124). However, significantly greater reductions in plasma concentrations of tumour necrosis factor α (TNF-α) (SMD -0.48, 95% CI -0.87, -0.08; P = 0.018) were achieved with ezetimibe/statin combination therapy. CONCLUSIONS: The results suggested that ezetimibe add-on to statin therapy is associated with an enhanced TNF-α-lowering effect compared with statin monotherapy. Owing to the emerging role of TNF-α in the pathogenesis of metabolic disorders, further investigations are required to unveil the translational relevance of this TNF-α-lowering effect.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025167
003      
CZ-PrNML
005      
20180711110234.0
007      
ta
008      
180709s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bcp.13250 $2 doi
035    __
$a (PubMed)28166606
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Dolezelova, Eva $u Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Charles University, Hradec Kralove, Czech Republic.
245    10
$a Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis / $c E. Dolezelova, E. Stein, G. Derosa, P. Maffioli, P. Nachtigal, A. Sahebkar,
520    9_
$a AIMS: Statins are known to influence the status of adipokines, which play a key role in the pathophysiology of cardiometabolic diseases. As the effect of ezetimibe as an add-on to statin therapy on the impact of statins on plasma adipokines levels is currently unclear, the aim of the present study was to investigate this through a meta-analysis of controlled trials. METHODS: A systematic review was performed, followed by a bibliographic search in PubMed, Medline, SCOPUS, Web of Science and Google Scholar databases. Quantitative data synthesis was performed using a fixed- or random-effects model (based on the level of interstudy heterogeneity) and the generic inverse variance weighting method. Effect sizes were expressed as standardized mean difference (SMD) and 95% confidence interval (CI). RESULTS: Meta-analysis of 23 controlled trials did not suggest any significant effect of adding ezetimibe on top of statin therapy on plasma concentrations of adiponectin (SMD 0.34, 95% CI -0.28, 0.96; P = 0.288), leptin (SMD -0.75, 95% CI: -2.35, 0.85; P = 0.360), plasminogen activator inhibitor 1 (SMD -1.06, 95% CI: -2.81, 0.69; P = 0.236) and interleukin 6 (SMD 0.30, 95% CI: -0.08, 0.67; P = 0.124). However, significantly greater reductions in plasma concentrations of tumour necrosis factor α (TNF-α) (SMD -0.48, 95% CI -0.87, -0.08; P = 0.018) were achieved with ezetimibe/statin combination therapy. CONCLUSIONS: The results suggested that ezetimibe add-on to statin therapy is associated with an enhanced TNF-α-lowering effect compared with statin monotherapy. Owing to the emerging role of TNF-α in the pathogenesis of metabolic disorders, further investigations are required to unveil the translational relevance of this TNF-α-lowering effect.
650    _2
$a adiponektin $x krev $7 D052242
650    _2
$a anticholesteremika $x farmakologie $x terapeutické užití $7 D000924
650    _2
$a ateroskleróza $x krev $x farmakoterapie $7 D050197
650    _2
$a kombinovaná farmakoterapie $x metody $7 D004359
650    _2
$a ezetimib $x farmakologie $x terapeutické užití $7 D000069438
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x farmakologie $x terapeutické užití $7 D019161
650    _2
$a interleukin-6 $x krev $7 D015850
650    _2
$a leptin $x krev $7 D020738
650    _2
$a inhibitor aktivátoru plazminogenu 1 $x krev $7 D017395
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a TNF-alfa $x krev $7 D014409
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a přehledy $7 D016454
700    1_
$a Stein, Evan $u Metabolic and Atherosclerosis Research Center, Cincinnati, OH, USA.
700    1_
$a Derosa, Giuseppe $u Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Center for the Study of Endocrine-Metabolic Pathophysiology and Clinical Research, University of Pavia, Pavia, Italy. Molecular Medicine Laboratory, University of Pavia, Pavia, Italy.
700    1_
$a Maffioli, Pamela $u Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. PhD School in Experimental Medicine, University of Pavia, Pavia, Italy.
700    1_
$a Nachtigal, Petr $u Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Sahebkar, Amirhossein $u Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. School of Medicine, University of Western Australia, Perth, WA, Australia.
773    0_
$w MED00000858 $t British journal of clinical pharmacology $x 1365-2125 $g Roč. 83, č. 7 (2017), s. 1380-1396
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28166606 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180711110525 $b ABA008
999    __
$a ok $b bmc $g 1317298 $s 1022088
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 83 $c 7 $d 1380-1396 $e 20170310 $i 1365-2125 $m British journal of clinical pharmacology $n Br J Clin Pharmacol $x MED00000858
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...